ClinicalTrials.gg
CompletedNCT04244084Updated May 17, 2022Results posted

Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection

A Phase 3 interventional study of MMH-407 and Placebo in Viral Respiratory Infection, sponsored by Materia Medica Holding. Completed at 26 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-17.

Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).

Read the detailed description

Design: multicenter, double blind, placebo-controlled, parallel group randomized clinical trial.

The study will enroll outpatients of either gender aged 18-70 years old with clinical manifestations of ARVI within the first day after the onset of the disease during seasonal ARVI morbidity.

After signing patient information sheet and informed consent form, medical history, thermometry, objective examination, laboratory tests and concomitant medication will be performed. Severity of ARVI symptoms is evaluated with 4-point scale.

The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI.

If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1) he/she will be randomized into one of two groups: the 1st group will take MMH-407 according to the dosage regimen for 5 days; the 2nd group will take Placebo according to MMH-407 dosage regimen for 5 days.

The study will use electronic patient diary for recording morning and evening axillary body temperature (measured using a mercury-free Geratherm Classic thermometer) and disease symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any aggravation in a patient's condition (if applicable, for safety evaluation/AE documentation) will also be recorded in a patient diary. The investigator will provide instructions on filling the diary; at Visit 1 the patient together with a doctor will record ARVI symptom severity and body temperature in the diary.

Patient will be observed for 14 days (screening, randomization - Day 1, treatment period - 5 days, follow-up - up to 2 days; deferred "phone visit" - Day 14).

During the treatment and follow-up period the patients or investigators will make 3 visits and the fourth "phone visit" will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5 and 7 (Visits 1, 2 and 3) - in a study center or at home; 2) "phone visit" (Visit 4) - on Day 14.

At Visits 2 and 3, the investigator will perform an objective examination, document changes in the symptoms and concomitant medications to check patient diaries. At Visit 3 compliance will be evaluated and laboratory tests will be performed. "Phone visit" is carried out to interview the patient about his/her condition, presence/absence of secondary bacterial/viral complications and use of antibiotics.

During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".

02

Conditions studied

  • Viral Respiratory Infection
03

In context

Lead sponsor

Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of either gender aged 18-70 years.
  2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 38.0°C at examination + total general symptoms score ≥4, nasal/throat/chest symptoms score ≥2.
  3. The first 24 hours after ARVI onset.
  4. Patients giving their consent to use reliable during the study.
  5. Signed patient information sheet ( form).

Exclusion criteria

Exclusion Criteria:

  1. Clinical symptoms of severe influenza/ARVI requiring hospitalization.
  2. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of illness.
  3. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and other pathology).
  4. Patients requiring antiviral medication prohibited within the study.
  5. Medical history of primary and secondary immunodeficiency.
  6. Medical history/suspicion of oncology of any localization (except for benign neoplasms).
  7. Aggravation or decompensation of chronic diseases affecting a patient's ability to participate in the clinical trial.
  8. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.
  9. Allergy/ to any component of the study drug.
  10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use methods during the trial.
  11. Course administration of the drug products specified in the section "Prohibited Concomitant Therapy" within two weeks prior to inclusion in the study.
  12. Patients who will not fulfill the requirements during the study or follow the order of administration of the studied drug products, from the Investigator's point of view.
  13. Medical history of mental diseases, alcoholism or drug abuse that according to the investigator's opinion will compromise compliance with the study procedures.
  14. Participation in other clinical trials for 3 months prior to enrollment in this study.
  15. Patients who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
  16. Patients who work for OOO "NPF "MATERIA MEDICA HOLDING" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    MMH-407

    Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.

    Drug: MMH-407

  • Placebo comparator
    Placebo

    According to the scheme of receiving MMN-407 until the end of the study.

    Drug: Placebo

Interventions

  • Oral use.

    Also known as: Raphamin

  • DrugPlacebo

    Oral use.

06

What researchers measure

Primary outcomes

  1. Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms

    Outcome Measure is evaluated on the basis of the "ARVI severity scale" to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR). ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

    Time frame: 14 days of observation.

Secondary outcomes

  1. Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)

    Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was "0" and the maximum value was "234" units (day\*score). Higher TSS and AUC scores meant worse results.

    Time frame: On days 1- 6 of the observation.

  2. Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)

    ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

    Time frame: On days 3, 4, 5 and 6 of observation.

  3. Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)

    Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

    Time frame: 14 days of observation.

  4. Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)

    Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection. Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

    Time frame: On days 3, 4, 5 and 6 of observation.

  5. Dosing Frequency of Antipyretics.

    Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.

    Time frame: On days 1, 2, 3 of therapy.

  6. Percentage of Patients Reporting Worsening of Illness

    Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.

    Time frame: From day 4 to day 14 of the observation period.

  7. Occurrence and Characteristics of Adverse Events (AEs)

    Severity of AEs, its causal relationship to the study drug, and outcomes.

    Time frame: From day 1 to day 7 of the treatment period.

  8. Changes in Vital Signs: Blood Pressure.

    Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).

    Time frame: On days 1, 5 and 7 of the treatment period.

  9. Changes in Vital Signs: Pulse Rate (Heart Rate).

    Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).

    Time frame: On days 1, 5 and 7 of the treatment period.

  10. Changes in Vital Signs: Respiration Rate (Breathing Rate).

    Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).

    Time frame: On days 1, 5 and 7 of the treatment period.

  11. Percentage of Patients With Clinically Relevant Laboratory Abnormalities

    Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.

    Time frame: From day 1 to day 7 of the treatment period.

07

Results

Posted Oct 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneMMH-407Placebo
Started118122
Completed118122
Not completed00

Outcome measures

PrimaryTime to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms

Outcome Measure is evaluated on the basis of the "ARVI severity scale" to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR). ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

Time frame:
14 days of observation.
Reported as:
Mean · days
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms
daysMMH-407Placebo
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms4.1 ± 1.95.0 ± 2.5
Statistical analysis
  • MMH-407 vs Placebo · ANCOVA · p = 0.0155 · Median difference (final values): -0.89 · 95% CI -1.61 to -0.17Site used as covariate
SecondarySeverity of ARVI (Clinically Diagnosed and/or PCR-confirmed)

Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was "0" and the maximum value was "234" units (day\*score). Higher TSS and AUC scores meant worse results.

Time frame:
On days 1- 6 of the observation.
Reported as:
Mean · day*score
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)
day*scoreMMH-407Placebo
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)48.5 ± 21.752.6 ± 24.0
Statistical analysis
  • MMH-407 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1839
SecondaryPercentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)

ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

Time frame:
On days 3, 4, 5 and 6 of observation.
Reported as:
Count of participants · Participants
Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)
ParticipantsMMH-407Placebo
Day 3158
Day 44438
Day 57470
Day 68685
Statistical analysis
  • MMH-407 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0640 (Day used as independent strata.)
SecondaryTime to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)

Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

Time frame:
14 days of observation.
Reported as:
Mean · days
Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)
daysMMH-407Placebo
Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)4.4 ± 2.24.8 ± 2.4
Statistical analysis
  • MMH-407 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1927
SecondaryPercentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)

Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection. Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".

Time frame:
On days 3, 4, 5 and 6 of observation.
Reported as:
Count of participants · Participants
Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)
ParticipantsMMH-407Placebo
Day 3123
Day 42822
Day 55438
Day 66048
Statistical analysis
  • MMH-407 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0014 (Day used as independent strata.)
SecondaryDosing Frequency of Antipyretics.

Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.

Time frame:
On days 1, 2, 3 of therapy.
Reported as:
Mean · number of doses
Dosing Frequency of Antipyretics.
number of dosesMMH-407Placebo
Day 10.30 ± 0.680.38 ± 0.67
Day 20.19 ± 0.480.24 ± 0.53
Day 30.03 ± 0.220.04 ± 0.20
Statistical analysis
  • MMH-407 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.2009
  • MMH-407 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.4717
  • MMH-407 vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5144
SecondaryPercentage of Patients Reporting Worsening of Illness

Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.

Time frame:
From day 4 to day 14 of the observation period.
Reported as:
Count of participants · Participants
Percentage of Patients Reporting Worsening of Illness
ParticipantsMMH-407Placebo
Percentage of Patients Reporting Worsening of Illness13
Statistical analysis
  • MMH-407 vs Placebo · Fisher Exact · p = 0.62
SecondaryOccurrence and Characteristics of Adverse Events (AEs)

Severity of AEs, its causal relationship to the study drug, and outcomes.

Time frame:
From day 1 to day 7 of the treatment period.
Reported as:
Number · Number of events
Occurrence and Characteristics of Adverse Events (AEs)
Number of eventsMMH-407Placebo
Number of AE911
Mild severity911
No relationship with the study drug811
Probable relationship to study drug10
SecondaryChanges in Vital Signs: Blood Pressure.

Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).

Time frame:
On days 1, 5 and 7 of the treatment period.
Reported as:
Mean · mmHg
Changes in Vital Signs: Blood Pressure.
mmHgMMH-407Placebo
Systolic blood pressure/Visit 1121.0 ± 10.0121.0 ± 10.1
Systolic blood pressure/Visit 2120.0 ± 8.5120.0 ± 8.4
Systolic blood pressure/Visit 3120.0 ± 8.2119.0 ± 9.4
Diastolic blood pressure/Visit 175.0 ± 7.575.1 ± 7.3
Diastolic blood pressure/Visit 274.9 ± 6.374.8 ± 6.4
Diastolic blood pressure/Visit 374.6 ± 6.674.8 ± 7.2
Statistical analysis
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.5981
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.4913
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.6441
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.8186
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.8931
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.5887
SecondaryChanges in Vital Signs: Pulse Rate (Heart Rate).

Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).

Time frame:
On days 1, 5 and 7 of the treatment period.
Reported as:
Mean · bpm
Changes in Vital Signs: Pulse Rate (Heart Rate).
bpmMMH-407Placebo
Heart rate/Visit 186.9 ± 12.988.0 ± 13.0
Heart rate/Visit 273.5 ± 7.474.4 ± 9.0
Heart rate/Visit 371.1 ± 5.871.7 ± 7.1
Statistical analysis
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.4426
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.5998
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.9710
SecondaryChanges in Vital Signs: Respiration Rate (Breathing Rate).

Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).

Time frame:
On days 1, 5 and 7 of the treatment period.
Reported as:
Mean · breaths/min
Changes in Vital Signs: Respiration Rate (Breathing Rate).
breaths/minMMH-407Placebo
Breathing rate/Visit 117.4 ± 1.617.5 ± 1.6
Breathing rate/Visit 216.6 ± 1.416.7 ± 1.4
Breathing rate/Visit 316.4 ± 1.316.4 ± 1.3
Statistical analysis
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.6197
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.7042
  • MMH-407 vs Placebo · Kruskal-Wallis · p = 0.7693
SecondaryPercentage of Patients With Clinically Relevant Laboratory Abnormalities

Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.

Time frame:
From day 1 to day 7 of the treatment period.
Reported as:
Count of participants · Participants
Percentage of Patients With Clinically Relevant Laboratory Abnormalities
ParticipantsMMH-407Placebo
Percentage of Patients With Clinically Relevant Laboratory Abnormalities01
Statistical analysis
  • MMH-407 vs Placebo · Fisher Exact · p = 1.000

Adverse events

Collected over During 6 days (start after taking the first dose of the study drug, during the entire period of the study therapy - 5 days and within 24 hours after the last dose of the study drug).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MMH-4070/118 (0%)0/118 (0%)9/118 (7.6%)
Placebo0/122 (0%)1/122 (0.8%)9/118 (7.6%)
Most frequent serious events
Most frequent serious events
EventMMH-407Placebo
Community-acquired pneumoniaInfections and infestations0/1181/122
Most frequent other events
Showing 10 of 16
Most frequent other events
EventMMH-407Placebo
Epigastric painGastrointestinal disorders2/1180/118
DiarrheaGastrointestinal disorders0/1181/118
Dry mouthGastrointestinal disorders1/1180/118
NauseaGastrointestinal disorders0/1181/118
SinusitisInfections and infestations0/1181/118
Purulent bronchitisInfections and infestations1/1181/118
Acute nasopharyngitisInfections and infestations1/1180/118
Acute tubootitisInfections and infestations1/1180/118
Herpes simplexInfections and infestations1/1181/118
Increase in the percentage of basophilsInvestigations0/1181/118

Baseline characteristics

Age, Continuous
Age, Continuous(years)MMH-407PlaceboTotal
Mean38.5 ± 12.638.5 ± 11.638.5 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)MMH-407PlaceboTotal
Female7968147
Male395493
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)MMH-407PlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)MMH-407PlaceboTotal
Russia118122240
08

Study locations

26 sites
  • Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology
    Barnaul, 656038, Russian Federation
  • City Hospital #5
    Barnaul, 656045, Russian Federation
  • Belgorod State National Research University, Hospital Therapy Department
    Belgorod, 308015, Russian Federation
  • Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways
    Chelyabinsk, 454000, Russian Federation
  • City Clinical Hospital #9 of the Ministry of Health of the Udmurt Republic
    Izhevsk, 426063, Russian Federation
  • Kazan State Medical University, Internal Medicine Department
    Kazan, 420012, Russian Federation
  • Kazan State Medical University, Professorial clinic
    Kazan, 420012, Russian Federation
  • Kuban State Medical University, Infectious Diseases and PhthisiopulmonologyDepartment
    Krasnodar, 350063, Russian Federation
  • Central Clinical Hospital of the Russian Academy of Sciences
    Moscow, 117593, Russian Federation
  • Moscow State Medical and Dental University named after A.I. Evdokimov, Pulmonology Laboratory
    Moscow, 127473, Russian Federation
  • Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways
    Nizhniy Novgorod, 603140, Russian Federation
  • City Clinical Hospital #10 of the Kanavinsky District of Nizhny Novgorod
    Nizhny Novgorod, 603011, Russian Federation
  • Podolsk City Clinical Hospital # 3
    Podolsk, 142105, Russian Federation
  • City Emergency Hospital Rostov-on-Don
    Rostov-on-Don, 344068, Russian Federation
  • Ryazan State Medical University named after academician I.P. Pavlov, Department of Outpatient Therapy and Preventive Medicine
    Ryazan, 390026, Russian Federation
  • Vvedensky City Clinical Hospital
    Saint Petersburg, 191180, Russian Federation
  • City Polyclinic #25 of the Nevsky District
    Saint Petersburg, 193312, Russian Federation
  • Medical Center "Reavita Med SPb"
    Saint Petersburg, 194354, Russian Federation
  • Road Clinical Hospital of JSC Russian Railways
    Saint Petersburg, 195271, Russian Federation
  • City Polyclinic #51
    Saint Petersburg, 196211, Russian Federation
  • City Polyclinic #34
    Saint Petersburg, 197198, Russian Federation
  • City Polyclinic #43
    Saint Petersburg, 198207, Russian Federation
  • Samara City Hospital #4
    Samara, 443056, Russian Federation
  • Scientific Medical Center for General Therapy and Pharmacology
    Stavropol, 355000, Russian Federation
  • Bashkir State Medical University, Internal Medicine Department
    Ufa, 450008, Russian Federation
  • Volgograd State Medical University
    Volgograd, 400131, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Apr 2020, 6 months.

Results were first posted in Oct 2021, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2019
First posted
Jan 28, 2020
StartActual
Oct 8, 2019
Primary completionActual
Apr 9, 2020
CompletionActual
Apr 9, 2020
Results first posted
Oct 6, 2021
Last update
May 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04244084
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Oct 8, 2019
Primary completion
Apr 9, 2020
Completion
Apr 9, 2020
Results posted
Oct 6, 2021
Last update
May 17, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MMH-407

Start the discussion